Illumina and FlowJo, LLC Partner to Develop and Co-Market a Software Solution for Single Cell
Genomics
Software for analysis and reporting of single cell data will advance research into cell function, disease
progression, and therapeutic response
Illumina, Inc. (NASDAQ: ILMN) and FlowJo, LLC, today announced a partnership to develop and co-market analysis software for single cell
next-generation sequencing (NGS) data. Under the agreement FlowJo, LLC, the producer of FlowJo, market-leading software for single
cell analysis, will develop a new software application. It will provide additional secondary and tertiary analysis and
visualization of datasets with an intuitive approach built on 19 years of experience working with cell biologists and immunologists
in single cell phenotyping. The application will seamlessly integrate with Illumina’s Single Cell RNA BaseSpace app, and provide a
solution accelerating discovery.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160810005216/en/
“We are excited to partner with Illumina on this project to bring new tools for analyzing and visualizing NGS data to cell
biology,” said Michael Stadnisky, PhD, CEO of FlowJo, LLC. “The new offering will enhance the power of single cell biology research
by empowering robust exploration of data from Illumina next-generation sequencing runs.”
“FlowJo, LLC is recognized for delivering reliable, high-quality and easy-to-use software solutions that allow cell biologists
to study phenotype in individual cells by flow cytometry,” said Rob Brainin, Vice President and General Manager, Applied Genomics
at Illumina. “We look forward to enabling our customers to bring these trusted FlowJo analytical capabilities to their
next-generation sequencing data.”
The software will complement the end-to-end commercial solution for high-throughput sequencing of single cells that Illumina
announced it is co-developing in partnership with Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb).
The companies expect the software to be available in Q1 2017.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
To learn more, visit www.illumina.com and follow @illumina.
About FlowJo, LLC
FlowJo, LLC is a privately owned life sciences software company in Ashland, Oregon. Based on technology developed at Stanford,
the company was founded in 1997 and provides the leading analysis platform for single cell flow and mass cytometry analysis. Their
software innovations enable collaboration, discovery, high-throughput analysis, and data leadership in flow and mass cytometry. For
more information, see www.FlowJo.com.
Illumina Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties, such as Illumina’s expectations regarding
the launch of any products. Important factors that could cause actual results to differ materially from those in forward-looking
statements include the application of generally accepted accounting principles, which are highly complex and involve many
subjective assumptions, estimates, and judgments, and the other factors detailed in Illumina’s filings with the Securities and
Exchange Commission, including its most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. Illumina assumes no obligation to update any forward-looking statements
after the date of this release.
Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
ir@illumina.com
or
Media:
Gwen Gordon
858-882-6822
pr@illumina.com
or
FlowJo, LLC
Media:
Caitlin Farquhar
800-366-6045
caitlinf@flowjo.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160810005216/en/